Guest Speaker

James Berry, MD, MPH
Regimen co-Lead (Regimen C)
Massachusetts General Hospital
Exploratory Endpoints

Endpoint Development Engine

DNA

Neurofilaments

Biomarkers (Blood, Urine, CSF)

Speech Analysis

Home Spirometry
The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial

Screening

Regimen Assignment

(n=160 for each regimen)

Regimen A

Regimen B

Regimen C

Regimen D

Regimen E

3:1 Randomization within each Regimen

(n=120 for active drug; n=40 for placebo)

Zilucoplan

Verdiperstat

CNM-Au8

Pridopidine

Trehalose

Shared Placebo

Open Label Extension

Open Label Extension

Open Label Extension

Open Label Extension
Enrollment Updates (as of July 7, 2022)

• **86** individuals have signed informed consent

• **59** individuals have been randomized within Regimen E

Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, **whether on the active drug or placebo, plays a critical role** in making the hope of finding a cure for ALS a reality
38 Sites Currently Activated for Regimen E

(as of 7/7/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

Lehigh Valley Health Network
Mass General Hospital
University of Kansas
University of Maryland
California Pacific Medical Center
Northwestern University
Virginia Commonwealth University
University of Nebraska
Washington University
Wake Forest University
Hospital for Special Care
Saint Alphonsus Regional
University of Massachusetts
Duke University
Barrow Neurological Institute
Georgetown University
Texas Neurology
Beth Israel Deaconess Medical Center
SUNY Upstate
Spectrum Health
Henry Ford Hospital
Essentia Health
University of Southern California
University of South Florida
University of Colorado
Providence Brain and Spine
University of Minnesota
Loma Linda University
University of Iowa
Swedish Medical Center
Ohio State University
University of Cincinnati
Thomas Jefferson University

UC San Francisco
Mayo Rochester
University of Washington
Vanderbilt University
UPMC

https://bit.ly/3g2NZr5
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:
https://bit.ly/3r6Nd2L

ALS Link sign-up:
https://bit.ly/3o2Ds3m

Upcoming Guest Speakers:
July 14th - Eufrosina Young, MD (Investigator at SUNY Upstate, New York)